Health Care • Biotechnology: Pharmaceutical Preparations
$38.86 ▲ +0.98
(+2.59%)
MKT CAP: $1.58B • VOL: 100.8K
52W L $28 52W H $60
PAHC // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-06-30 | FY 2024
FILED 2024-06-30 | FY 2023
FILED 2023-06-30 |
|---|---|---|---|
| Revenue (Total Sales) | $1.30B | $1.02B | $977.9M |
| YoY Revenue Growth % | +27.4% | +4.1% | — |
| Gross Profit | $399.9M | $313.1M | — |
| Gross Margin % | 30.9% | 30.8% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $110.5M | $53.3M | $71.8M |
| Operating Margin % | 8.5% | 5.2% | 7.3% |
| Net Income (GAAP) | $48.3M | $2.4M | $32.6M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $80.1M | $87.6M | $13.3M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | $80.1M | $87.6M | $13.3M |
| FCF Margin % | 6.2% | 8.6% | 1.4% |
| Return on Invested Capital (ROIC %) | 9.9% | 5.2% | — |
| Cash & Short-Term Equivalents | $55.5M | $67.1M | — |
| Total Debt (Short + Long Term) | $603.6M | $622.9M | — |
| Total Stockholders' Equity | $332.4M | $246.8M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR PAHC.